GOLDMAN SACHS GROUP INC - CORCEPT THERAPEUTICS INC ownership

CORCEPT THERAPEUTICS INC's ticker is CORT and the CUSIP is 218352102. A total of 226 filers reported holding CORCEPT THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 0.71 and the average weighting 0.1%.

Quarter-by-quarter ownership
GOLDMAN SACHS GROUP INC ownership history of CORCEPT THERAPEUTICS INC
ValueSharesWeighting
Q2 2024$16,523,570
+50.9%
508,574
+17.0%
0.00%
+50.0%
Q1 2024$10,950,647
-36.7%
434,722
-18.4%
0.00%
-33.3%
Q4 2023$17,304,044
+55.4%
532,760
+30.4%
0.00%
+50.0%
Q3 2023$11,131,626
+37.7%
408,575
+12.5%
0.00%0.0%
Q2 2023$8,082,691
-7.5%
363,267
-10.0%
0.00%0.0%
Q1 2023$8,738,316
-9.3%
403,431
-14.9%
0.00%0.0%
Q4 2022$9,631,023
+88911.3%
474,201
+12.4%
0.00%
-33.3%
Q3 2022$10,820
+47.4%
421,993
+36.7%
0.00%
+50.0%
Q2 2022$7,339
-99.9%
308,640
-11.5%
0.00%0.0%
Q1 2022$7,850,000
+7.7%
348,586
-5.3%
0.00%
+100.0%
Q4 2021$7,287,000
-35.7%
368,046
-36.1%
0.00%
-50.0%
Q3 2021$11,330,000
+25.6%
575,683
+40.4%
0.00%0.0%
Q2 2021$9,018,000
-21.7%
409,935
-15.3%
0.00%
-33.3%
Q1 2021$11,515,000
-32.6%
484,016
-25.9%
0.00%
-40.0%
Q4 2020$17,079,000
+105.8%
652,873
+37.0%
0.01%
+150.0%
Q3 2020$8,298,000
-48.7%
476,714
-50.4%
0.00%
-60.0%
Q2 2020$16,160,000
+57.6%
960,711
+11.4%
0.01%
+25.0%
Q1 2020$10,251,000
+82.5%
862,130
+85.8%
0.00%
+300.0%
Q4 2019$5,616,000
+40.7%
464,111
+64.4%
0.00%0.0%
Q3 2019$3,991,000
+67.3%
282,325
+31.9%
0.00%0.0%
Q2 2019$2,386,000
-63.0%
213,970
-61.1%
0.00%
-50.0%
Q1 2019$6,455,000
-16.6%
549,837
-5.1%
0.00%0.0%
Q4 2018$7,744,000
-3.8%
579,631
+0.9%
0.00%0.0%
Q3 2018$8,053,000
-39.0%
574,400
-31.6%
0.00%
-50.0%
Q2 2018$13,195,000
+41.6%
839,377
+48.1%
0.00%
+100.0%
Q1 2018$9,321,000
-23.8%
566,602
-16.3%
0.00%
-33.3%
Q4 2017$12,231,000
-15.7%
677,232
-9.9%
0.00%0.0%
Q3 2017$14,505,000
+350.6%
751,563
+175.5%
0.00%
+200.0%
Q2 2017$3,219,000
+36.5%
272,815
+26.7%
0.00%0.0%
Q1 2017$2,359,000
+145.7%
215,292
+62.8%
0.00%
Q4 2016$960,000
+18.4%
132,266
+6.0%
0.00%
Q3 2016$811,000
+144.3%
124,793
+105.5%
0.00%
Q2 2016$332,000
+39.5%
60,719
+19.2%
0.00%
Q1 2016$238,000
-2.5%
50,954
+3.6%
0.00%
Q4 2015$244,000
+130.2%
49,177
+74.7%
0.00%
Q3 2015$106,000
-49.8%
28,154
-19.7%
0.00%
Q2 2015$211,000
-53.8%
35,069
-78.5%
0.00%
Q2 2014$457,000
+277.7%
163,159
+488.7%
0.00%
Q1 2014$121,000
+72.9%
27,717
+27.3%
0.00%
Q4 2013$70,000
+191.7%
21,775
+41.9%
0.00%
Q3 2013$24,000
-65.7%
15,350
-68.8%
0.00%
Q4 2012$70,000
+16.7%
49,124
+130.3%
0.00%
Q3 2012$60,000
-59.5%
21,330
-35.3%
0.00%
Q2 2012$148,000
-67.1%
32,957
-71.2%
0.00%
Q1 2012$450,000114,3580.00%
Other shareholders
CORCEPT THERAPEUTICS INC shareholders Q2 2023
NameSharesValueWeighting ↓
INGALLS & SNYDER LLC 8,372,001$98,287,0004.68%
TANAKA CAPITAL MANAGEMENT INC 79,574$934,0002.82%
Consonance Capital Management LP 3,747,453$43,995,0002.78%
S&T BANK/PA 613,740$7,205,0001.62%
AJ WEALTH STRATEGIES, LLC 595,834$6,995,0001.16%
Capital Impact Advisors, LLC 193,694$2,522,0001.12%
TEALWOOD ASSET MANAGEMENT INC 154,615$1,815,0000.77%
AMI ASSET MANAGEMENT CORP 722,932$8,487,0000.63%
Birchview Capital, LP 50,000$587,0000.37%
FEDERATED HERMES, INC. 11,176,281$131,210,0000.32%
View complete list of CORCEPT THERAPEUTICS INC shareholders